$15.00
Manufacturer: Ukraine
adults Antisecretory therapy, in cases where it is not possible to use the oral route of administration, for example gastroesophageal reflux disease in patients with esophagitis and / or severe reflux symptoms; treatment of stomach ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs); warnings of stomach and duodenal ulcers associated with NSAID therapy in patients who are at risk. Short-term maintenance of hemostasis and prevention of repeated bleeding in patients after endoscopic treatment of acute bleeding due to gastric ulcer or duodenal ulcer. Children between 1 and 18 yEars and Nose of age Antisecretory therapy, if it is not possible to use the oral route of administration, for example gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and / or severe reflux symptoms.
Description
Ezonexa 20 mg Composition
active substance: esomeprazole;
1 tablet contains esomeprazole magnesium dihydrate 21.75 mg, which is equivalent to esomeprazole 20 mg; or esomeprazole magnesium dihydrate 43.5 mg, which is equivalent to esomeprazole 40 mg;
excipients: methacrylate copolymer dispersion, talc, triethyl citrate, hypromelose, spherical sugar, magnesium stearate, hydroxypropyl cellulose, glycerol monostearate, polysorbate 80, microcrystalline cellulose, povidone, macrogol 6000, crospovidone, sodium stearyl fumarate; for a dosage of 20 mg: Opadry Pink 03B34284 (hypromellose, titanium dioxide (E171), macrogol 400, iron oxide red (E172), iron oxide yellow (E172)); for a dosage of 40 mg: Opadry Pink 03B34285 (hypromellose, titanium dioxide (E171), macrogol 400, iron oxide red (E172), iron oxide yellow (E172)).
Ezonexa 20 mg Dosage form.
Enteric tablets.
Basic physical and chemical properties:
tablets of 20 mg: light pink, biconvex, elliptical, coated tablets measuring (6.55 ± 0.4) mm × (13.6 ± 0.6) mm;
40 mg tablets: pink, biconvex, elliptical, coated tablets measuring (8.2 ± 0.5) mm × (17 ± 0.6) mm.
Ezonexa 20 mg Pharmacotherapeutic group.
Drugs for the treatment of peptic ulcers and gastroesophageal reflux disease. Proton pump inhibitors.
ATX code А02В С05.
Pharmacological properties
Pharmacodynamics.
Esomeprazole is the S-isomer of omeprazole, which reduces the secretion of hydrochloric acid in the stomach due to a specific targeted mechanism of action. It is a specific inhibitor of the proton pump in the parietal cell. The R- and S-isomers of omeprazole have the same pharmacodynamic activity.
Esomeprazole is a weak base, it concentrates and becomes active in the highly acidic environment of the secretory tubules of the parietal cell, where it inhibits the H + K + -ATPase enzyme – the proton pump, and also suppresses basal and stimulated acid secretion.
Indications
Adults
Gastroesophageal reflux disease (GERD):
treatment of erosive reflux esophagitis;
long-term treatment of patients with healed esophagitis in order to prevent relapse;
symptomatic treatment of GERD.
In combination with appropriate antibacterial drugs for the eradication of Helicobacter pylori:
treatment of duodenal ulcer due to Helicobacter pylori;
prevention of recurrence of peptic ulcers in patients with ulcers caused by Helicobacter pylori.
Patients requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs):
healing of stomach ulcers caused by the use of NSAIDs;
prevention of stomach and duodenal ulcers caused by the use of NSAIDs in patients at risk.
Long-term treatment after intravenous administration of the drug to prevent recurrence of bleeding from peptic ulcers.
Treatment of Zollinger-Ellison syndrome.
Children over the age of 12.
Gastroesophageal reflux disease (GERD):
treatment of erosive reflux esophagitis;
long-term treatment of patients with healed esophagitis to prevent relapse;
symptomatic treatment of gastroesophageal reflux disease.
In combination with antibiotics in the treatment of duodenal ulcers caused by Helicobacter pylori.
Contraindications
Known hypersensitivity to esomeprazole, substituted benzimidazoles, or other components of the drug.
The drug, like other proton pump inhibitors, should not be used with nelfinavir.
Children’s age (under 12 years old).
Recent Reviews